Setmelanotide
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Rhythm · Phase 3 · Completed · Enrollment 19
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Run-in Period: Setmelanotide 2 mg QD | n/r | n/r | n/r | n/r |
| Run-in Period: Setmelanotide 2.5 mg QD | n/r | n/r | n/r | n/r |
| Run-in Period: Setmelanotide 3 mg QD | n/r | n/r | n/r | n/r |
| DB Period: Setmelanotide 20 mg QW | n/r | n/r | n/r | n/r |
| DB Period: Setmelanotide 25 mg QW | n/r | n/r | n/r | n/r |
| DB Period: Setmelanotide 3 mg QD | n/r | n/r | n/r | n/r |
| DB Period: Setmelanotide 30 mg QW | n/r | n/r | n/r | n/r |
| OL Period: Setmelanotide 20 mg QW | n/r | n/r | n/r | n/r |
| OL Period: Setmelanotide 25 mg QW | n/r | n/r | n/r | n/r |
| OL Period: Setmelanotide 30 mg QW | n/r | n/r | n/r | n/r |
Not shown
- Run-in Period: Setmelanotide 2 mg QD: endpoint not reported
- Run-in Period: Setmelanotide 2.5 mg QD: endpoint not reported
- Run-in Period: Setmelanotide 3 mg QD: endpoint not reported
- DB Period: Setmelanotide 20 mg QW: endpoint not reported
- DB Period: Setmelanotide 25 mg QW: endpoint not reported
- DB Period: Setmelanotide 3 mg QD: endpoint not reported
- DB Period: Setmelanotide 30 mg QW: endpoint not reported
- OL Period: Setmelanotide 20 mg QW: endpoint not reported
- OL Period: Setmelanotide 25 mg QW: endpoint not reported
- OL Period: Setmelanotide 30 mg QW: endpoint not reported